Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer

Global cancer statistics

Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text

Medicine, Oncology, Cancer Epidemiology +15

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Rafael G. Amado, Michael Wolf, Marc Peeters et al. · Journal of Clinical Oncology · 2008 · 3.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

Thierry André, C. Boni, Matilde Navarro et al. · Journal of Clinical Oncology · 2009 · 2.3K citations

Medicine, Oncology, Surgery +16

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study

The Lancet · 2007 · 1.4K citations

Medicine, Oncology, Surgery +11